In the Pipeline/home/corante/public_html/pipeline/
en-usderekb.lowe@gmail.com2015-07-30T06:04:55-05:00hourly12000-01-01T12:00+00:00Another Alzheimer's IPOhttp://pipeline.corante.com/archives/2015/07/30/another_alzheimers_ipo.php
I've been saying a lot of unkind things about Axovant, the insta-company that's taking a discarded GSK Alzheimer's candidate and running with it. But thanks to Adam Feuerstein, I have another company to roll my eyes about. They have a...77851@/home/corante/public_html/pipeline/Alzheimer's Disease2015-07-30T06:04:55-05:00Underwhelming Alzheimer's Results From Biogen and Lillyhttp://pipeline.corante.com/archives/2015/07/22/underwhelming_alzheimers_results_from_biogen_and_lilly.php
OK, we have some Alzheimer's data to talk about this morning. Biogen's antibody aducanumab, about which people have been wildly enthusiastic, showed very little effect on mental decline at a 6mg dose, the company reported today. Note that the Phase...77839@/home/corante/public_html/pipeline/Alzheimer's Disease2015-07-22T07:29:32-05:00Axovant's Stock Coveragehttp://pipeline.corante.com/archives/2015/07/20/axovants_stock_coverage.php
I've bemoaned the Axovant IPO here a couple of times already. Via Jean Fonteneau on Twitter (his full Axovant coverage is here), we have the chart at left. In case you were wondering how "research" and "recommendations" are done on...77834@/home/corante/public_html/pipeline/Alzheimer's Disease2015-07-20T12:04:28-05:00Alzheimer's Disposes of Another Ideahttp://pipeline.corante.com/archives/2015/07/02/alzheimers_disposes_of_another_idea.php
In case you were wondering, you can add "MAO-B inhibition" to the long, long list of Things That Don't Do Any Good For Alzheimer's. I'm not sure how much hope anyone had for that program (at either Roche or Evotec),...77823@/home/corante/public_html/pipeline/Alzheimer's Disease2015-07-02T07:02:00-05:00Two Alzheimer's Updates (Lilly and TauRx)http://pipeline.corante.com/archives/2015/06/30/two_alzheimers_updates_lilly_and_taurx.php
When you look at the stock charts of the major pharma companies, there's not a lot of excitement to be had. Until you get to Eli Lilly, that is. Over the last year, the S&P 500 is up about 5%,...77820@/home/corante/public_html/pipeline/Alzheimer's Disease2015-06-30T06:14:15-05:00More on Axovant's IPOhttp://pipeline.corante.com/archives/2015/06/09/more_on_axovants_ipo.php
Update: the IPO went off at the top of its range, I am sorry to report. More here from FierceBiotech, and I agree with John Carroll's take. I wrote just recently about Axovant and their plans to go public with...77781@/home/corante/public_html/pipeline/Business and Markets2015-06-09T06:13:18-05:00An Alzheimer's IPO, Because Why Nothttp://pipeline.corante.com/archives/2015/05/12/an_alzheimers_ipo_because_why_not.php
Now here's someone with optimism to burn, compost, and scatter to the winds. According to FierceBiotech, Vivek Ramaswamy has started a company called Axovant Pharmaceuticals, and their asset is a 5-HT6 antagonist from GSK. It goes back to the SmithKline...77742@/home/corante/public_html/pipeline/Alzheimer's Disease2015-05-12T10:21:49-05:00Sulfur, Sulfur, Sulfurhttp://pipeline.corante.com/archives/2015/04/28/sulfur_sulfur_sulfur.php
Does anyone know of any phosphatase inhibitors that aren't hideous? I ask this because someone sent along a question about this paper, from last August, that I'd missed at the time (press release here, but the paper's open-access as well)....77720@/home/corante/public_html/pipeline/Drug Assays2015-04-28T06:20:41-05:00Another Argument For Tauhttp://pipeline.corante.com/archives/2015/03/31/another_argument_for_tau.php
Just to give most everyone in the Alzheimer's field a little more reason to doubt themselves, the Mayo Clinic has published a study suggesting that the pathology associated with tau protein (neurofibrillary tangles, NFT) is (as some have always maintained)...77679@/home/corante/public_html/pipeline/Alzheimer's Disease2015-03-31T08:17:33-05:00Biogen's Alzheimer's Datahttp://pipeline.corante.com/archives/2015/03/20/biogens_alzheimers_data.php
If you're a rabid biotech investor, you already know all about Biogen's data this morning. If you're sane, or insane in some other, more interesting direction, then here's what's up: last December, the company released some Phase I data suggesting...77660@/home/corante/public_html/pipeline/Alzheimer's Disease2015-03-20T06:37:18-05:00Gamma-Secretase Inhibitors: The Wrong Way Around?http://pipeline.corante.com/archives/2015/03/09/gammasecretase_inhibitors_the_wrong_way_around.php
Here's an Alzheimer's mystery, and that area was not lacking for them before. A paper in Neuron from Harvard/Mass General/Brigham & Women's says that we may have been thinking about gamma-secretase the wrong way around. (Here's a press release from...77636@/home/corante/public_html/pipeline/Alzheimer's Disease2015-03-09T06:47:46-05:00New Alzheimer's Research in the UKhttp://pipeline.corante.com/archives/2015/02/18/new_alzheimers_research_in_the_uk.php
Oxford University's new Drug Discovery Institute is making a big push in dementia and Alzheimer's. Update: link fixed, I hope. One one level, that's good news, because this is a tough area that needs all the well-placed shots that can...77599@/home/corante/public_html/pipeline/Alzheimer's Disease2015-02-18T07:09:09-05:00"From All This You'd Imagine, That There Must Be Something Learned. . ."http://pipeline.corante.com/archives/2015/02/05/from_all_this_youd_imagine_that_there_must_be_something_learned_.php
Eli Lilly's phase III clinical trial of semagacestat, a gamma-secretase inhibitor, was a notable disaster. The drug did absolutely nothing at all for Alzheimer's patients - in fact, if anything, it made them slightly worse. The amyloid hypothesis was not...77578@/home/corante/public_html/pipeline/Alzheimer's Disease2015-02-05T07:57:03-05:00Another Alzheimer's Antibody Goes Downhttp://pipeline.corante.com/archives/2014/12/19/another_alzheimers_antibody_goes_down.php
The clinical failure rate for disease-modifying Alzheimer's therapies remains perfect, unfortunately: a flat 100%. The latest news is from Roche. Their in-licensed amyloid-targeting antibody (gantenerumab, from MorphoSys) came up empty on an interim trial analysis. Other trials are apparently continuing,...77512@/home/corante/public_html/pipeline/Alzheimer's Disease2014-12-19T07:28:11-05:00Another Alzheimer's Antibody Goes Downhttp://pipeline.corante.com/archives/2014/12/19/another_alzheimers_antibody_goes_down.php
The clinical failure rate for disease-modifying Alzheimer's therapies remains perfect, unfortunately: a flat 100%. The latest news is from Roche. Their in-licensed amyloid-targeting antibody (gantenerumab, from MorphoSys) came up empty on an interim trial analysis. Other trials are apparently continuing,...77512@/home/corante/public_html/pipeline/Alzheimer's Disease2014-12-19T07:28:11-05:00